Search / Trial NCT00002283

A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Launched by JACOBUS PHARMACEUTICAL · Aug 30, 2001

Trial Information

Current as of December 06, 2024

Completed

Keywords

Trimethoprim Sulfamethoxazole Combination Aids Related Opportunistic Infections Pneumonia, Pneumocystis Carinii Dapsone Acquired Immunodeficiency Syndrome

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).
  • Patients with the following are excluded:
  • History of allergic reaction to dapsone.
  • Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).
  • Patients subsequently found to be glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from the study and treated with another regimen.
  • Prior Medication:
  • Excluded:
  • Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).
  • Patients who are glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from the study and treated with another regimen.
  • Hospitalized patients with first episode of Pneumocystis carinii pneumonia (PCP) documented by GIEMSA or methenamine stain.
  • * Patients must:
  • Be willing and able to give informed consent.
  • Be expected to survive 1 week without therapy.
  • Have less than 48 hours of treatment for Pneumocystis carinii pneumonia (PCP) for this episode.

About Jacobus Pharmaceutical

Jacobus Pharmaceutical is a specialized biopharmaceutical company dedicated to advancing innovative therapies for rare and complex diseases. With a strong focus on research and development, Jacobus is committed to improving patient outcomes through the development of novel treatments that address unmet medical needs. The company prides itself on its collaborative approach, working closely with healthcare professionals, regulatory agencies, and patient advocacy groups to ensure that its clinical trials are designed to meet the highest standards of safety and efficacy. Through its rigorous scientific methodologies and commitment to excellence, Jacobus Pharmaceutical strives to make a meaningful impact in the lives of patients and their families.

Locations

Princeton, New Jersey, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials